Ahmad Qaddour, MD
Cardiovascular Disease · Wichita, KSNPI 1003160987
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 335 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations.
Across 335 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Novartis$595
- Johnson & Johnson$574
- Amgen$478
- Merck$366
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$243
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,13997%
- Education$1623%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 56 | $1,032 |
| Novartis | 46 | $595 |
| Johnson & Johnson | 45 | $574 |
| Amgen | 30 | $478 |
| Merck | 24 | $366 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $243 |
| E.r. Squibb & Sons, L.L.C. | 15 | $236 |
| Novo Nordisk | 10 | $200 |
| Pfizer | 12 | $189 |
| Bayer | 7 | $154 |
| Boehringer Ingelheim | 9 | $149 |
| Actelion Pharmaceuticals US, Inc. | 3 | $134 |
| AstraZeneca | 8 | $134 |
| Biotronik Inc. | 10 | $117 |
| Boston Scientific | 6 | $110 |
| Amarin Pharma, Inc. | 5 | $91 |
| Sanofi-aventis U.S. LLC | 6 | $80 |
| Bardy Diagnostics, Inc. | 4 | $73 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $49 |
| Inspire Medical Systems, Inc. | 2 | $41 |
| Lexicon Pharmaceuticals, Inc. | 2 | $33 |
| Surmodics, Inc. | 4 | $30 |
| United Therapeutics Corporation | 1 | $23 |
| Astellas Pharma US Inc | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Abiomed | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Davol Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Edwards Lifesciences | 1 | $15 |
| Canon Medical Systems USA, Inc. | 1 | $15 |
| Cvrx, Inc. | 1 | $14 |
| Preventice Services, LLC | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
How this compares
$5,301 in reported general payments places this provider in the 70th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 231 | $214,436 |
| EliquisApixaban | 256 | $197,776 |
| JardianceEmpagliflozin | 183 | $157,445 |
| EntrestoSacubitril/Valsartan | 159 | $115,178 |
| Repatha SureclickEvolocumab | 60 | $59,843 |
| OzempicSemaglutide | 32 | $31,236 |
| BrilintaTicagrelor | 33 | $25,950 |
| MounjaroTirzepatide | 19 | $25,806 |
| FarxigaDapagliflozin Propanediol | 16 | $14,397 |
| Potassium Chloride | 389 | $7,462 |
| Metoprolol Succinate | 531 | $6,024 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 184 | $5,687 |
| CorlanorIvabradine Hcl | 11 | $5,613 |
| Ranolazine ErRanolazine | 27 | $5,433 |
| SotalolSotalol Hcl | 325 | $5,336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $574 | $214,436231 claims |
| PfizerEliquis | $189 | $197,776256 claims |
| Boehringer IngelheimJardiance | $149 | $157,445183 claims |
| NovartisEntresto | $595 | $115,178159 claims |
| AstraZenecaBrilinta, Farxiga | $134 | $40,34849 claims |
| Novo NordiskOzempic | $200 | $31,23632 claims |
| AmgenCorlanor | $478 | $5,61311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 175 cardiovascular disease providers in Kansas.
Other cardiovascular disease in Wichita
- Bassem ChehabWichita$482K
- Joseph GalichiaWichita$177K
- Wassim ShaheenWichita$137K
- Layne ReusserWichita$91K
- Aziz MaksoudWichita$81K
- Hossein AmiraniWichita$18K
- Ahmed MohamedWichita$17K
- Daniel AlvarezWichita$16K
- Freidy EidWichita$13K
- Mohamad FarhatWichita$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.